Literature DB >> 2856541

Failures of intravenous Rh immune globulin prophylaxis: an analysis of the reasons for such failures.

J M Bowman1, J M Pollock.   

Abstract

Universal administration of an ion exchange column prepared Rh immune globulin (RhIG-IV) antepartum at 28 weeks' gestation and postpartum to 9,295 Rh negative women delivering Rh positive babies has reduced the prevalence of Rh immunization from the expected 601 to 25 (a protection rate of 95.9%). Rh immunization, despite universal Rh prophylaxis, developed in 25 women; eight before antenatal prophylaxis was administered, 17 after antenatal prophylaxis was administered. Residual Rh immunization is caused by small fetal transplacental hemorrhages (TPH) (greater than or equal to 0.01 mL of fetal blood) before antenatal prophylaxis (15%) and by significant fetal TPH (greater than or equal to 0.05 mL of fetal blood) between 30 and 38 weeks' gestation (18%); TPH was too great, in some instances, for residual passive Rh antibody to give protection. Although a reduction of 62% (five of eight) of early Rh immunization and 82% (14 of 17) of later Rh immunization might be achieved by addition of 16 weeks' to 20 weeks' gestation and 34 weeks' gestation Rh prophylaxis; and a reduction of 84% overall (21 of 25) might be achieved by universal fetal TPH screening every 2 weeks from 10 weeks' gestation until delivery, with administration of RhIG when a small early fetal TPH or a significant later fetal TPH is detected, all of these programs are costly in terms of prevention of perinatal mortality and in terms of cost per quality adjusted life year gained. We believe that the costs outweigh the benefit that would be achieved. Therefore, a residual Rh immunization prevalence of 0.24% to 0.31% during or after each Rh positive pregnancy in patients at risk is to be expected despite universal 28 weeks' gestation antenatal and postnatal Rh prophylaxis.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2856541     DOI: 10.1016/s0887-7963(87)70010-8

Source DB:  PubMed          Journal:  Transfus Med Rev        ISSN: 0887-7963


  12 in total

Review 1.  The role of antenatal immunoprophylaxis in the prevention of maternal-foetal anti-Rh(D) alloimmunisation.

Authors:  Giancarlo Maria Liumbruno; Angelo D'Alessandro; Federica Rea; Vanessa Piccinini; Liviana Catalano; Gabriele Calizzani; Simonetta Pupella; Giuliano Grazzini
Journal:  Blood Transfus       Date:  2010-01       Impact factor: 3.443

Review 2.  Anti-D prophylaxis in 1997: the Edinburgh Consensus Statement.

Authors:  D James
Journal:  Arch Dis Child Fetal Neonatal Ed       Date:  1998-05       Impact factor: 5.747

3.  Pump up the volume? The routine early use of colloid in very preterm infants.

Authors:  P Hope
Journal:  Arch Dis Child Fetal Neonatal Ed       Date:  1998-05       Impact factor: 5.747

4.  Recommendations for the prevention and treatment of haemolytic disease of the foetus and newborn.

Authors:  Francesco Bennardello; Serelina Coluzzi; Giuseppe Curciarello; Tullia Todros; Stefania Villa
Journal:  Blood Transfus       Date:  2015-01       Impact factor: 3.443

5.  The importance of antenatal prevention of RhD immunisation in the first pregnancy.

Authors:  Slavica Dajak; Damir Roje; Željka Hundrić Hašpl; Pera Erceg Maglić
Journal:  Blood Transfus       Date:  2014-01-02       Impact factor: 3.443

6.  Plasma half-lives and bioavailability of human monoclonal Rh D antibodies BRAD-3 and BRAD-5 following intramuscular injection into Rh D-negative volunteers.

Authors:  J Goodrick; B Kumpel; D Pamphilon; I Fraser; G Chapman; B Dawes; D Anstee
Journal:  Clin Exp Immunol       Date:  1994-10       Impact factor: 4.330

7.  Routine antenatal anti-D prophylaxis in women who are Rh(D) negative: meta-analyses adjusted for differences in study design and quality.

Authors:  Rebecca M Turner; Myfanwy Lloyd-Jones; Dilly O C Anumba; Gordon C S Smith; David J Spiegelhalter; Hazel Squires; John W Stevens; Michael J Sweeting; Stanislaw J Urbaniak; Robert Webster; Simon G Thompson
Journal:  PLoS One       Date:  2012-02-03       Impact factor: 3.240

Review 8.  The prevention and management of haemolytic disease of the newborn.

Authors:  M Contreras; M de Silva
Journal:  J R Soc Med       Date:  1994-05       Impact factor: 18.000

9.  Complement Plays a Critical Role in Inflammation-Induced Immunoprophylaxis Failure in Mice.

Authors:  Vicente Escamilla-Rivera; Manjula Santhanakrishnan; Jingchun Liu; David R Gibb; James E Forsmo; Ellen F Foxman; Stephanie C Eisenbarth; C John Luckey; James C Zimring; Krystalyn E Hudson; Sean R Stowell; Jeanne E Hendrickson
Journal:  Front Immunol       Date:  2021-06-25       Impact factor: 8.786

10.  Bias modelling in evidence synthesis.

Authors:  Rebecca M Turner; David J Spiegelhalter; Gordon C S Smith; Simon G Thompson
Journal:  J R Stat Soc Ser A Stat Soc       Date:  2009-01       Impact factor: 2.483

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.